Lilly Drug Cuts Vision Loss in Diabetic Eye Disease
Posted on: Tuesday, 13 June 2006, 12:01 CDT
An analysis of data from two phase III trials suggest that Eli Lilly's investigational drug ruboxistaurin mesylate reduced vision loss caused by the effects of diabetic retinopathy.
The drug, whose proposed brand name is Arxxant, reduced the risk of sustained moderate vision loss by 41% when compared to placebo in patients with moderate to severe, non-proliferative diabetic retinopathy (DR).
Vision loss occurred in 6.1% of patients treated with ruboxistaurin compared to 10.2% of patients treated with placebo. The pooled analysis of the trials was presented at the American Diabetes Association scientific sessions in Washington.
"These data are exciting because they show that ruboxistaurin has the potential to be the first oral therapy to specifically reduce the risk of vision loss caused by diabetic retinopathy," said Dr Lloyd Paul Aiello, lead investigator of the study and associate professor of ophthalmology at Harvard Medical School.
Source: Datamonitor
Related Articles
- U.S. Adults With Diabetes Fear Blindness or Vision Loss More Than Premature Death
- Ruboxistaurin Reduced Vision Loss in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy in a New Study
- Drug Shown to Cut Diabetics' Vision Loss
- Investigational Treatment Ruboxistaurin Demonstrated Promise in Reducing the Occurrence of Vision Loss Caused By Diabetic Retinopathy
- Lilly Drug Helps Reduce Diabetic Vision Loss: Study
- Molecule Linked to Vision Loss in Diabetics
- Study Shows New Compound May Reduce Risk of Vision Loss in Patients With Diabetes
- Joslin-Chaired Study Shows New Compound May Reduce Risk of Vision Loss in Patients With Diabetes
- Different Patterns of Insulin Resistance in Relatives of Type 1 Diabetic Patients With Retinopathy or Nephropathy: The Genesis France-Belgium Study
 |
 |
User Comments (0)
RSS Feeds